Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes.
The thiazolidinediones troglitazone and BRL 49653 improve insulin sensitivity in humans and animals with insulin resistance. Adipose tissue lipoprotein lipase is an insulin-sensitive enzyme. We examined the effects of thiazolidinediones on lipoprotein lipase expression in adipocytes. When added to 3T3-F442A, 3T3-L1, and rat adipocytes in culture, troglitazone and BRL 49653 inhibited lipoprotein lipase activity. This inhibition was observed at concentrations as low as 0.1 microM and within 2 h after addition of the drug. Lipoprotein lipase activity was inhibited in differentiated adipocytes as well as the differentiating cells. Despite this decrease in enzyme activity, these drugs increased mRNA levels in undifferentiated 3T3-F442A and 3T3-L1 cells and had no effect on mRNA expression or synthesis of lipoprotein lipase in differentiated cells. Western blot analysis showed that these drugs did not affect the mass of the enzyme protein. Lipoprotein lipase activity in cultured Chinese hamster ovary cells was not inhibited by troglitazone. Glucose transport, biosynthesis of lipids from glucose or the biosynthesis of proteins were unaffected by thiazolidinediones in differentiated cells, whereas glucose transport and lipid biosynthesis were increased when these drugs were added during differentiation. These results show that troglitazone and BRL 49653 have a specific, post-translational inhibitory effect on lipoprotein lipase in adipocytes, yet they promote lipid accumulation and differentiation in preadipocytes.
Ranganathan
S
S
Department of Medicine, Division of Endocrinology, University of Arkansas for Medical Sciences and the John L. McClellan Veterans Affairs Medical Center, Little Rock, Arkansas 72205, USA.
Kern
P A
PA
D017667:Adipocytes / Q000187:drug effects / Q000201:enzymology*; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D016466:CHO Cells / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D002839:Chromans / Q000494:pharmacology*; D006224:Cricetinae; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D005947:Glucose / Q000493:pharmacokinetics; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance / Q000502:physiology; D008055:Lipids / Q000096:biosynthesis; D008071:Lipoprotein Lipase / Q000037:antagonists & inhibitors*; D051379:Mice; D014176:Protein Biosynthesis; D012333:RNA, Messenger / Q000187:drug effects; D051381:Rats; D000077154:Rosiglitazone; D013234:Stem Cells / Q000187:drug effects / Q000201:enzymology; D013844:Thiazoles / Q000494:pharmacology*; D045162:Thiazolidinediones; D014280:Triglycerides / Q000378:metabolism; D000077288:Troglitazone
D002839:Chromans; D004791:Enzyme Inhibitors; D007328:Insulin; D008055:Lipids; D012333:RNA, Messenger; D013844:Thiazoles; D045162:Thiazolidinediones; D014280:Triglycerides; D000077154:Rosiglitazone; D008071:Lipoprotein Lipase; D000077288:Troglitazone; D005947:Glucose